AI drug-discovery company Insilico Medicine signed a multiyear R&D collaboration with French pharma Servier worth up to $888 million to jointly discover and develop oncology candidates using Insilico’s Pharma.AI platform. The deal follows Insilico’s recent $292 million Hong Kong IPO and includes up-front and near-term payments to accelerate target ID and lead optimization. Servier will lead clinical validation and global commercialization for candidates arising from the collaboration; Insilico will provide AI-driven discovery tools and is eligible for milestone and royalty payments. The partnership underscores a continued industry pivot toward large-risk-sharing AI alliances as pharma outsources early discovery to algorithmic platforms. The arrangement signals appetite among mid-sized and global pharmas to pair traditional development expertise with machine-learning lead-generation; near-term readouts from preclinical candidate selection will determine whether AI partners convert discovery speed into de-risked clinical assets.